- $59.59m
- $64.40m
- 18
- 46
- 12
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -154.17% | ||
| Return on Equity | -188.47% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Directors
- Rene Sindlev CHM (59)
- Mark Dybul CEO (58)
- Luisa Puche CFO (58)
- Henrik Gronfeldt-Sorensen DRC (49)
- Gregg Alton IND (55)
- Carol Brosgart IND (70)
- Jayne McNicol IND (55)
- Carl Sandler IND (49)
- James Sapirstein IND (60)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 18th, 2011
- Public Since
- November 18th, 2014
- No. of Shareholders
- 197
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 177,392,908
- Address
- Century City Medical Plaza, LOS ANGELES, 90067
- Web
- https://renovarobio.com/
- Phone
- +1 2127630184
- Auditors
- Sadler, Gibb & Associates, LLC
Upcoming Events for RENB
Q4 2025 Renovaro Inc Earnings Release
Similar to RENB
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Renovaro share price?
As of Today at 22:55 UTC, shares in Renovaro are trading at $0.34. This share price information is delayed by 15 minutes.
How has the Renovaro share price performed this year?
Shares in Renovaro last closed at $0.34 and the price had moved by -77.46% over the past 365 days. In terms of relative price strength the Renovaro share price has underperformed the S&P500 Index by -79.67% over the past year.
What are the analyst and broker recommendations for Renovaro?
There is no consensus recommendation for this security.
Find out moreWhat is the Renovaro dividend yield?
Renovaro does not currently pay a dividend.
Does Renovaro pay a dividend?
Renovaro does not currently pay a dividend.
When does Renovaro next pay dividends?
Renovaro does not currently pay a dividend.
How do I buy Renovaro shares?
To buy shares in Renovaro you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Renovaro?
As of the previous close price of $0.34, shares in Renovaro had a market capitalisation of $59.59m.
Where are Renovaro shares listed?
Here are the trading details for Renovaro:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RENB
What kind of share is Renovaro?
Based on an overall assessment of its quality, value and momentum Renovaro is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Renovaro share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Renovaro share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Renovaro. Over the past six months, its share price has underperformed the S&P500 Index by -37.14%.
As of the last closing price of $0.34, shares in Renovaro were trading -54.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Renovaro PE Ratio?
The Renovaro PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Renovaro?
Renovaro's management team is headed by:
- Rene Sindlev - CHM
- Mark Dybul - CEO
- Luisa Puche - CFO
- Henrik Gronfeldt-Sorensen - DRC
- Gregg Alton - IND
- Carol Brosgart - IND
- Jayne McNicol - IND
- Carl Sandler - IND
- James Sapirstein - IND